Pages that link to "Q42684364"

The following pages link to Herpes zoster (Q42684364):

Displaying 23 items.

• Concurrent Ramsay Hunt syndrome and disseminated herpes zoster in a patient with relapsed chronic lymphocytic leukemia. (Q30372270) (← links)
• Genetic variation in the HLA region is associated with susceptibility to herpes zoster (Q35020397) (← links)
• Development and Validation of a Laboratory-Developed Multiplex Real-Time PCR Assay on the BD Max System for Detection of Herpes Simplex Virus and Varicella-Zoster Virus DNA in Various Clinical Specimens. (Q35607449) (← links)
• Anti-cytokine autoantibodies in postherpetic neuralgia (Q36198740) (← links)
• Is herpes zoster an additional complication in old age alongside comorbidity and multiple medications? Results of the post hoc analysis of the 12-month longitudinal prospective observational ARIZONA cohort study (Q36602847) (← links)
• Mitochondrial Haplogroups as a Risk Factor for Herpes Zoster. (Q37383627) (← links)
• The herpes zoster subunit vaccine (Q38728931) (← links)
• Longterm Effectiveness of Herpes Zoster Vaccine among Patients with Autoimmune and Inflammatory Diseases (Q38905074) (← links)
• Self-reported herpes zoster, pain, and health care seeking in the Health and Retirement Study: implications for interpretation of health care-based studies (Q39765566) (← links)
• Amenamevir, a novel helicase-primase inhibitor, for treatment of herpes zoster: A randomized, double-blind, valaciclovir-controlled phase 3 study (Q40133568) (← links)
• Pharmacokinetics and Safety of Amenamevir in Healthy Subjects: Analysis of Four Randomized Phase 1 Studies (Q47108365) (← links)
• Healthcare utilization and costs among patients with herpes zoster and solid tumor malignancy on chemotherapy: A retrospective cohort study (Q47116736) (← links)
• The Influence of Hepatic and Renal Impairment on the Pharmacokinetics of a Treatment for Herpes Zoster, Amenamevir (ASP2151): Phase 1, Open-Label, Single-Dose, Parallel-Group Studies (Q47133959) (← links)
• Immunogenicity and Safety of an Adjuvanted Herpes Zoster Subunit Vaccine Coadministered With Seasonal Influenza Vaccine in Adults Aged 50 Years or Older (Q47613536) (← links)
• Increased Risk of Atrial Fibrillation in the Early Period after Herpes Zoster Infection: a Nationwide Population-based Case-control Study. (Q55171550) (← links)
• A Fatal Case of Atypical Disseminated Herpes Zoster in a Patient with Meningoencephalitis and Seizures Associated with Steroid Immunosuppression (Q57051412) (← links)
• Cost-effectiveness of vaccination of immunocompetent older adults against herpes zoster in the Netherlands: a comparison between the adjuvanted subunit and live-attenuated vaccines (Q59790939) (← links)
• The Economic Burden and Impact on Quality of Life of Herpes Zoster and Postherpetic Neuralgia in Individuals Aged 50 Years or Older in Italy (Q64248474) (← links)
• Incidence of herpes zoster and postherpetic neuralgia in Italian adults aged ≥50 years: A prospective study (Q64262221) (← links)
• The Impact of Reactogenicity After the First Dose of Recombinant Zoster Vaccine on the Physical Functioning and Quality of Life of Older Adults: An Open-Label, Phase III Trial (Q91763570) (← links)
• Association between Herpes Zoster and Osteoporosis: A Nested Case-Control Study Using a National Sample Cohort (Q92999763) (← links)
• Burden of Herpes Zoster in the Japanese Population with Immunocompromised/Chronic Disease Conditions: Results from a Cohort Study Claims Database from 2005-2014 (Q93230247) (← links)
• Clinical Efficacy of Ultrasound-Mediated Transdermal Lidocaine and Capsaicin Delivery for the Treatment of Allodynia Caused by Herpes Zoster (Q96306883) (← links)